pyridinoline

3-hydroxypyridinium derivative collagen crosslink; structure

Also Known As:

hydroxylysyl pyridinoline; hydroxylysylpyridinoline; Pyridinium, 4-(2-amino-2-carboxyethyl)-1-(5-amino-5-carboxy-2-hydroxypentyl)-3-(3-amino-3-carboxypropyl)-5-hydroxy-, hydroxide, inner salt

Networked: 625 relevant articles (18 outcomes, 82 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - pyridinoline: 625

Experts

1.	Inaba, Masaaki: 7 articles (02/2006 - 10/2002)
2.	Ishimura, Eiji: 7 articles (02/2006 - 10/2002)
3.	Nishizawa, Yoshiki: 7 articles (02/2006 - 10/2002)
4.	Okuno, Senji: 6 articles (02/2006 - 10/2002)
5.	Fraser, W D: 6 articles (12/2005 - 09/2000)
6.	Yamakawa, Tomoyuki: 5 articles (02/2006 - 05/2005)
7.	Sato, Y: 5 articles (08/2001 - 04/2000)
8.	Delmas, P D: 4 articles (07/2006 - 01/2000)
9.	Garnero, P: 4 articles (07/2006 - 06/2001)
10.	Ueda, Misako: 4 articles (02/2006 - 10/2002)

Related Diseases

1.	Bone Resorption 11/01/1992 - "The method shows considerable promise as a rapid and specific index of human bone resorption rates, with greatly improved specificity and convenience over total pyridinoline analysis. " 11/24/2000 - "Femur weights and serum concentrations of pyridinoline, a reliable marker of bone resorption, were measured at the end of the study period. " 11/01/2020 - "Serum pyridinoline (bone resorption marker) was 20 to 27% higher in NC2 hens than in the other groups, with no effects on other bone markers. " 10/15/2018 - "Finally, in control mice serum levels of a marker of bone resorption (pyridinoline crosslinks) and the osteoclast activator RANKL significantly increased upon OVX; however, no such OVX-induced increase was observed in cKO mice. " 09/01/2013 - "The nonadherent population of BMSCs harvested from the long bone diaphysis of KO animals formed more osteoclasts, a finding that was associated with increased circulatory levels of pyridinoline, a marker of bone resorption. "
2.	Prostatic Neoplasms (Prostate Cancer) 02/01/1997 - "Pyridinoline cross-linked carboxyterminal telopeptide might assist PSA and bone scintigraphy in monitoring metastatic bone activity of prostatic cancer." 08/01/1998 - "Also, urinary pyridinoline and deoxypyridinoline were compared in 2 groups of patients with metastatic prostate cancer of the bone who demonstrated progression or positive response to treatment. " 11/01/1996 - "Also, urinary pyridinoline and deoxypyridinoline were compared in 2 groups of patients with metastatic prostate cancer of the bone who demonstrated progression or positive response to treatment. " 09/01/2001 - "Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer." 08/01/1998 - "Measurement of urinary pyridinoline and deoxypyridinoline may provide a useful marker of prostate cancer metastatic to bone and may be useful in monitoring the response to treatment."
3.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 08/01/1998 - "Levels of urinary pyridinoline and deoxypyridinoline in urine in patients with bony metastatic prostate cancer were significantly greater than levels in patients with benign prostatic hyperplasia or localized prostate cancer. " 04/01/1994 - "Urinary excretion of pyridinoline and deoxypyridinoline was significantly greater in patients with metastatic carcinoma of the prostate compared with patients with either benign prostatic hyperplasia (Mann-Whitney-Wilcoxon rank sum analysis, p < 0.00004 and 0.002, respectively) or localized prostate cancer (Mann-Whitney-Wilcoxon, p < 0.00001 and 0.00005, respectively). " 08/01/1998 - "Urinary pyridinoline and deoxypyridinoline were measured in patients with benign prostatic hyperplasia, clinically localized prostate cancer and prostate cancer with bone metastases. " 11/01/1996 - "Levels of pyridinoline and deoxypyridinoline in urine, and the level of alkaline phosphatase in serum from patients with bone metastatic prostate cancer were significantly greater than levels in patients with benign prostatic hyperplasia or localized prostate cancer. " 11/01/1996 - "Urinary pyridinoline, urinary deoxypyridinoline, serum alkaline phosphatase and serum osteocalcin were measured in patients with benign prostatic hyperplasia, clinically localized prostate cancer and prostate cancer with bone metastases. "
4.	Disease Progression 08/01/1998 - "Serial measurement of urinary pyridinoline and deoxypyridinoline was correlated with a positive response to treatment (decreased) and with clinical progression of disease (increased) before detection of new bone lesions by bone scintigraphy. " 11/01/1996 - "Serial measurement of urinary pyridinoline and deoxypyridinoline was correlated with a positive response to treatment (decreased) and with clinical progression of disease (increased) before detection of new bone lesions by bone scintigraphy. " 04/01/1994 - "Serial measurements of pyridinoline and deoxypyridinoline progressively increased in 3 patients with clinical progression documented by new metastatic lesions by bone scan. "
5.	Neoplasm Metastasis (Metastasis) 02/01/1997 - "Pyridinoline cross-linked carboxyterminal telopeptide, an osteoclastic marker, reflected the extent of bone metastasis more accurately than PSA and other bone markers. " 07/01/1996 - "The aim of this study was to evaluate the urinary pyridinium crosslink levels in breast cancer with or without osseous involvement, and to correlate it with serial doses of CA 15-3. 285 breast cancer patients (226 free of disease and 59 with bone metastases) were measured for both pyridinoline and CA 15-3. In the metastatic patients the mean values of the two markers were significantly higher than in non evident disease patients (P = < 0.01 and p = < 0.001 respectively). " 07/01/1996 - "Abnormal values over the normal were found in 22% for pyridinoline and 11% for CA 15-3 in patients free of disease while the normal values observed in patients with bone metastases were 22% for pyridinoline and 39% for CA 15-3. Tandem dosage of CA 15-3, was highly sensitive but site-aspecific, and pyridinoline, which is bone specific, may be useful chiefly in the monitoring of breast cancer treatment, since many physiological conditions such as age, menopausal status and variation over 24 hours, and cost effectiveness will influence the use of pyridinoline during follow-up." 12/01/1997 - "Levels of urine pyridinoline (U-Pyr) excretion and serum carboxy-terminal propeptide of type 1 procollagen (P1CP) in patients with bone metastasis were significantly higher than those in patients without bone metastasis (P < 0.05). " 02/01/1997 - "During the observation periods, no metastatic bone lesion developed and no significant changes in pyridinoline and deoxypyridinoline occurred in the five patients without bone metastasis. "

Related Drugs and Biologics

1.	deoxypyridinoline
2.	Alkaline Phosphatase
3.	Collagen Type I (Type I Collagen)
4.	Osteocalcin
5.	Biomarkers (Surrogate Marker)
6.	Calcium
7.	Collagen
8.	Hydroxyproline (4 Hydroxyproline)
9.	Pamidronate (Aredia)
10.	Phosphorus (Red Phosphorus)

Related Therapies and Procedures

1.	Therapeutics
2.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
3.	Ovariectomy (Oophorectomy)
4.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
5.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)